secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0000950170-25-085439
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen to effect 1-for-25 reverse stock split to regain Nasdaq compliance
---------------------------------------------------------------------------

- Reverse split effective 5:00 p.m. ET June 16, 2025; post-split trading begins June 17.
- Outstanding shares reduced from ~101.1M to ~4.0M; new CUSIP 31572Q881.
- No fractional shares issued; cash paid in lieu of fractional interests.
- Split approved by stockholders at June 4, 2025 annual meeting.
- Aims to meet Nasdaq minimum bid price requirement (Rule 5450(a)(1)).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025085439/0000950170-25-085439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025085439/fgen-20250610.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-085439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer